In Blossom’s latest research briefing, analysts examine:
The company plans to expand its drug discovery platform and advance its lead candidates through Phase I clinical trials.
Read More
Exclusive rights to the data from the Phase IIa study in alcoholism enhance Awakn’s clinical programmes.
Read MorePharmaTher raises C$10m in private placement.
Mycrodose Therapeutics closes oversubscribed financing round.
NeonMind shares strategy for roll-out of branded clinics.
Small Pharma completes Phase I clinical trial of DMT.
Tryp Therapeutics submits IND application for Phase II clinical trials.
Mydecine files patent for psilocybin analogue.
Psyence Group and Pure Extracts announce venture to research psilocybin.
BetterLife files patent for LSD derivative.
Levitee Labs announces DTC eligibility approval.
Wake Network receives certificate of drug registration in Jamaica.
HAVN Life signs distribution MOU with Mycrodose Therapeutics.
Emyria shares update from MDMA analogue screening.
NeonMind appoints Dr Gustavo Vazquez to Speciality Clinics Advisory Board.
Lobe Sciences releases data from preclinical trials.
ATMA creates Therapist Network Services Program for therapist training.
Nikean Foundation gives University Health Network C$5m for psychedelic research.
Clinical trials with psilocybin and ketamine begin in Texas following new legislation.
The Independent – How psychedelics changed my life.
MindMed and Liechti Lab share psilocybin research results.
Drug possession effectively decriminalised in Scotland.
Grand Rapids City approves resolution on decriminalisation.
Bill filed in Florida to study benefits of psychedelic medicines.